MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff.

Members Present: Cathy Zehrung, RPh; Phillip Levine, PhD; Tracy Klein, PhD, FNP; William Origer, MD
Members Present by Phone: David Pass, MD; James Slater, PharmD; Stacy Ramirez, PharmD; Zahia Esber, MD
Staff Present: Israel Harden, Kathy Ketchum, RPh, MPA:HA; Megan Herink, PharmD, BCPS; Richard Holsapple, RPh; Roger Citron, RPh; Ted Williams, PharmD; Trevor Douglass, DC, MPH; Valerie Smith
Staff Present by Phone: Bing-Bing Liang, PharmD; Brandy Fouts, PharmD
Audience: Kenith Fritsche (OSU); Paul Banken (NNI); Amir Karimzadeh (Forest); Jamie Damm (Vertex); Jeff Evans (Astellas); Venus Holder (Lily); Linda Posta (Astellas); Jennifer Kammerer (Astellas); Shannon Beatty (MedImmune); Paul Nielsen (MedImmune); David Barba (Forest); Jean Colabianchi (Sunovion); Steve Fuldon (Otsuka); Lori Howarth (Bayer); Bruce Smith (GSK); Jim Graves (BMS); Barry Benson (Merck); Cheryl Fletcher (Abbvie); Richard Kosesan

I. CALL TO ORDER
   a. The meeting was called to order at approximately 1pm.
   b. The Committee reviewed the revised membership report.
   c. No new conflicts of interest were declared.
   d. The November 29, 2012 meeting minutes were reviewed.
ACTION: Approved as is.
   e. Dr. Douglass presented a department update.

II. OPERATING PROCEDURES
   a. Mr. Citron presented amended operating procedures document. Dr. Klein recommended changing “physicians” to “prescribers” in item 5 of the Conduct of Meetings section of the document.
ACTION: Approved as amended.
ACTION: Approved as is.
   c. Dr. Herink presented on clinical procedures.
ACTION: Approved as is.

III. NEW BUSINESS
   *Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
a. Dr. Williams presented on FDB drug file updates.

ACTION: Approved.

b. Dr. Herink presented an abbreviated new drug evaluation on Retisert implant and recommended asking the HERC to evaluate the surgical procedures of both the fluocinolone and dexamethasoneocular implants for line placement.

ACTION: Approved.

c. Dr. Liang presented an abbreviated class update on overactive bladder medications and recommended comparing costs of agents in class in executive session and continue to include both ER and IR options as preferred alternatives. Dr. Liang also presented a new drug evaluation on mirabegron recommending making it non-preferred. Linda Posta from Astellas provided public comment.

*ACTION: After Executive Session, the Committee recommended continuing ER and IR options as alternatives, but make hyoscyamine rapid tabs preferred and to make Oscimin®, hyoscyamine drops, mirabegron and Gelnique® non-preferred. The Committee also recommended making tolerodine non-preferred with a 90 day grandfather.

d. Dr. Fouts presented a new drug evaluation on aclidinium bromide and recommended making it non-preferred. Amir Karimzadeh from Forest presented public comment.

*ACTION: After Executive Session, the Committee approved the recommendations.

e. Dr. Herink presented an abbreviated new drug evaluation on Combivent Respimat® recommending making Combivent Respimat® and Combivent MDI® non-preferred and require a step through therapy with either a short acting beta agonist OR a short acting anticholinergic and grandfather current utilizers.

*ACTION: After Executive Session, the Committee approved the recommendations.

f. Dr. Herink presented drug class scans recommending:
   1. Macrolide Antibiotics – no further review at this time and make all erythromycin products non-preferred.

*ACTION: After Executive Session, the Committee approved the recommendations.

2. Fluoroquinolone Antibiotics – no further review at this time and make Noroxin® non-preferred.

*ACTION: After Executive Session, the Committee approved the recommendations.

3. GI: PPI’s and H2A’s – no further review at this time, update prior authorization criteria, make omeprazole tablets, all OTC H2A products and cimetidine non-preferred, grandfathering cimetidine indefinitely.

*ACTION: After Executive Session, the Committee approved the recommendations.

4. Antihistamines – no further review at this time and make all OTC products non-preferred.

*ACTION: After Executive Session, the Committee approved the recommendations.

IV. The meeting was adjourned at approximately 3:30pm.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)